Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › paclitaxel

paclitaxel

38 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of paclitaxel

470 trials tracked of paclitaxel: 133 in phase 3 or 4 and 85 with published results. The most-cited published study has 3356 citations.

470Trials tracked
133Phase 3 & 4
0Recruiting
85With published results
Phase distribution
Phase 4 5 Phase 3 128 Phase 2 285 Phase 1 43 Other / NA 9
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Completed · 3,356 cited
  2. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,857 cited
  3. Phase 3 A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) Completed · 2,667 cited
  4. Phase 3 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed · 2,575 cited
  5. Phase 3 A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) Completed · 2,157 cited
  6. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Completed · 1,807 cited
Show 44 more trials
  1. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed · 1,504 cited
  2. Phase 3 A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] Completed · 1,428 cited
  3. Phase 3 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Completed · 1,372 cited
  4. Phase 3 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Completed · 1,185 cited
  5. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,184 cited
  6. Phase 3 Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed · 1,136 cited
  7. Phase 3 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) Completed · 738 cited
  8. Phase 3 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed · 586 cited
  9. Phase 3 A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Completed · 520 cited
  10. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 504 cited
  11. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression Completed · 438 cited
  12. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 421 cited
  13. Phase 3 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 410 cited
  14. Phase 3 A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer Completed · 403 cited
  15. Phase 3 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed · 343 cited
  16. Phase 3 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Completed · 322 cited
  17. Phase 3 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 310 cited
  18. Phase 3 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Completed · 307 cited
  19. Phase 3 A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Completed · 304 cited
  20. Phase 3 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 300 cited
  21. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 295 cited
  22. Phase 3 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Completed · 291 cited
  23. Phase 3 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Completed · 245 cited
  24. Phase 3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed · 234 cited
  25. Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 225 cited
  26. Phase 3 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Completed · 208 cited
  27. Phase 3 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed · 205 cited
  28. Phase 3 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Completed · 200 cited
  29. Phase 3 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Completed · 194 cited
  30. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 194 cited
  31. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 182 cited
  32. Phase 3 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Completed · 168 cited
  33. Phase 3 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Completed · 167 cited
  34. Phase 3 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Completed · 163 cited
  35. Phase 3 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Completed · 150 cited
  36. Phase 3 Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. Completed · 145 cited
  37. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 144 cited
  38. Phase 3 A Phase III Study of NK105 in Patients With Breast Cancer Completed · 131 cited
  39. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer Completed · 114 cited
  40. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
  41. Phase 3 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Completed · 104 cited
  42. Phase 3 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study Completed · 100 cited
  43. Phase 3 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer Completed · 98 cited
  44. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Completed · 94 cited

Showing the 50 most-cited and recently-updated of 470 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients
OB/GYN & Women's Health Phase II
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients Can a shorter, more intense chemo regimen help prevent early-stage HER2-positive breast cancer from returning?
A phase II trial evaluated a dose-dense regimen of cyclophosphamide, paclitaxel, and trastuzumab after surgery in 20 patients with stage I-I…
For women with early-stage HER2-positive breast cancer, a key question is whether a shorter, more intense chemotherapy schedule after surger…
CT.gov Mar 30, 2026
Study Validates Genotype Predictor of TIPN in African American Breast Cancer Patients
OB/GYN & Women's Health Phase II
Study Validates Genotype Predictor of TIPN in African American Breast Cancer Patients Could your genes predict nerve pain from breast cancer treatment?
This phase II trial with 249 participants evaluates a germline predictor of taxane-induced peripheral neuropathy (TIPN) in African American …
A genetic marker may predict severe nerve pain from breast cancer chemo in African American patients, with docetaxel possibly causing fewer …
CT.gov Mar 28, 2026